Reply to Scheetz et al. and to Meyer and Thalhammer [7]

Clinical Infectious Diseases

Volumn 42, Issue 3, 2006, Pages 437-438

  Trotman, Robin L ^a   Willaimson, J C ^a   Shoemaker, D M ^b   Salzer, W L ^b  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CILASTATIN PLUS IMIPENEM;

ANTIBIOTIC RESISTANCE; BRAIN TOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CONTINUOUS HEMOFILTRATION; DRUG ACCUMULATION; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG SAFETY; FLOW RATE; HUMAN; KIDNEY DYSFUNCTION; LETTER; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 31044437685     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/499538     Document Type: Letter

References (5)

1. Scheetz MN, Scarsi KK, Ghossein C, Hurt KM, Zembower TR, Postelnick MJ. Dosage adjustment of antimicrobials for continuous venovenous hemofiltration based on patient-specific information [letter]. Clin Infect Dis 2005; 42: 436-7 (in this issue).
2. Meyer B, Thalhammer F. Linezolid and continuous venovenous hemofiltration [letter] Clin Infect Dis 2005; 42:435-6 (in this issue).
3. Trotman RL, Williamson JC, Shoemaker M, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41: 1159-66.
4. Pestotnik SL, Classen DC, Evans RS, Stevens LE, Burke JP. Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Ann Pharmacother 1993; 27:497-501.
5. Meyer B, Kornek GV, Nikfardjam M, et al. Multiple-dose pharmacokinetics of linezolid during continuous venonenous hemofiltration. J Antimicrob Chemother 2005; 56:172-9.